Despite some manufacturers claiming a vaccine will be available as early as October, White House health advisor Dr. Anthony Fauci has repeatedly cautioned optimism on the media timelines. Now Fauci is advising the public the vaccine may have limited "durability" in terms of its ability to provide long-term immunity.
During an interview with JAMA Editor Howard Bauchner, Fauci said “it likely isn’t going to be a long duration of immunity. When you look at the history of coronaviruses, the common coronaviruses that cause the common cold, the reports in the literature are that the durability of immunity that’s protective ranges from three to six months to almost always less than a year, That’s not a lot of durability and protection."
In COVIDVax.news's last weekly COVID-19 Vaccine Availability report, manufacturers are hovering in the Phase I/II stage of vaccine development as each manufacturer races to be the first to bring a vaccine to market. However, the fastest vaccine ever developed end to end took four years, back in 1967. The need for a solution for COVID-19 is greatly accelerating those timelines but forces the scientific community to speed up what is typically a multiple year-long process.
“You can have everything you think that’s in place and you don’t induce the kind of immune response that turns out to be protective and durably protective,” said Fauci, “So one of the big unknowns is, will it be effective? Given the way the body responds to viruses of this type, I’m cautiously optimistic that we will with one of the candidates get an efficacy signal.”
Meanwhile, COVID-19 treatments take on a faster timeline, one of which coming from Russia expected to hit Russian hospitals this month.
Fauci draws his caution from the decades of research on Coronavirus, a common family of viruses which typically affects animals.
Other experts are joining in Fauci's concern including Dr. Paul Offit, the director of the Vaccine Education center at the Children's Hospital of Philadelphia and Anna Durbin, a vaccine researcher at Johns Hopkins University. Upon a recently announced timeline by Moderna Pharmaceuticals, Durbin expressed of their two-week wait period to measure results of antibody production, "That’s very early. We don’t know if those antibodies are durable..."